Baixar PDF
Artigo anterior
Voltar à página
Artigo seguinte
If you have problems to see the content please click here
Outros usuários também visualizaram estes artigos
Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. II: CAR-T cell therapy for patients with CD19+ acute lymphoblastic leukemia
Adriana Seber; Claudio Galvão de CastroJunior; Lucila N. Kerbauy; Alexandre V. Hirayama; Carmem Bonfim; Juliana Folloni Fernandes; Mair Souza; Rony Schafell; Samir Nabhan; Sandra Regina Loggetto; Belinda Pinto Simões; Vanderson Rocha; Marcos de Lima; Renato L. Guerino-Cunha; Henrique Bittencourt;
Hematol Transfus Cell Ther. 2021;43 Supl 2:S13-21
BLINATUMOMAB BRIDGING THERAPY FOR EFFECTIVE MANAGEMENT OF MRD IN PRO-B ALL WITH CNS INVOLVEMENT: A CASE REPORT OF POST TRANSPLANT PATIENT AT 23 MONTHS AFTER ALLOGENIC HEMATOPOIETIC CELL TRANSPLANTATION
Ceren Dehri Bah¿i; Birol Güvenç;
Hematol Transfus Cell Ther. 2024;46 Supl 7:S72-3
Minimal residual disease assessment in acute lymphoblastic leukemia by 4-color flow cytometry: Recommendations from the MRD Working Group of the Brazilian Society of Bone Marrow Transplantation
Maura R.V. Ikoma-Colturato; Miriam P. Beltrame; Felipe M. Furtado; Glicinia Pimenta; Elaine Sobral da Costa; Ana Paula Azambuja; Mariester Malvezzi; Mihoko Yamamoto;
Hematol Transfus Cell Ther. 2021;43:332-40